Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 24 September 2016, the Multiple Sclerosis Clinical Trials Unit hosted 102 patients and family members/carers at the Unipart Conference Centre in Oxford.

In the morning Dr Matthew Craner updated everyone on the topics presented at a recent MS conference and Dr Jacqueline Palace talked about the UK Risk Sharing Scheme, which helped make second-line treatments more available for patients with MS.

Fascinating set of presentations. Complicated sciences presented in an accessible and interesting way. Well done to all.
- Patient attendee

Several early-career researchers then presented the projects they are currently working on in the field of MS. During lunch there were posters from researchers detailing their research as well as an opportunity to get information leaflets from a local MS Society branch and sign up for the brain bank.

In the afternoon three key speakers gave detailed presentations on stem cells (Dr Andrew Weir), using clinical data to improve treatment of MS (Professor Paul Matthews), and genetics (Professor Lars Fugger).

 

Similar stories

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.